Follow The Filings

JNJ Johnson & Johnson

Health Care, filed as JOHNSON & JOHNSON (COM), Equity As of 2026 Q3 among managers we track Quote on Google Finance, opens in a new tab

Bought by 4 managers in 2026 Q2, sold by 6

  • 5 Owners
  • #24
  • Max 2.6%
  • Master 0.05%
  • $11M
  • 2 reduce

In 2026 Q3 Kentucky Trust and Murphy Pohlad trimmed Johnson & Johnson.

Who owns this now

Largest portfolio weights among holders, up to 2.6% (Kentucky Trust Co., Kentucky Trust). Not free-float ownership.

  1. Kentucky Trust Co. Reduce 2.6%
  2. Murphy Pohlad Reduce 1.2%
  3. Kenneth Dedeker 0.26%
  4. Torray Investment Partners 0.14%
  5. David Katz 0.04%

Who owns JNJ

Sorted by value, long equity only, as of 2026 Q3.

History
Kentucky Trust Co., Kentucky Trust 2.6% Reduce −4.1% 19,927 $5.3M History
Murphy Pohlad, Murphy Pohlad Asset Management 1.2% Reduce −3.2% 13,159 $3.5M History
Torray Investment Partners 0.14% Hold 4,141 $1.1M History
Kenneth Dedeker, Dedeker Financial 0.26% Hold 1,697 $449K History
David Katz, Matrix Asset Advisors 0.04% Hold 1,622 $429K History

5 current, options excluded

Weight bar: held both quarters added sold at this quarter’s reported price

Insider trades

Open-market buys and sales by JNJ's executives, directors and 10% owners in the last 12 months, from their Form 4s

All JNJ insider trades
  • $258K bought by 1 insider
  • $92.3M sold by 6 insiders outside a trading plan
  • None no planned (10b5-1) sales
  1. Timothy Schmid Chair
    Sale
    $9.2M 33,597 shares at $274.74 57% of stake
    Traded Sep 2 Filed Sep 4
    ↗
  2. Jennifer L Taubert EVP, WWC. Innovative Medicine
    Sale
    $4M 15,000 shares at $263.36 7.2% of stake
    Traded Aug 17 Filed Aug 18
    ↗
  3. Joaquin Duato CEO
    Sale
    $32.2M 123,291 shares at $261.17 31% of stake
    Traded Aug 13 Filed Aug 14
    ↗
  4. Joaquin Duato CEO
    Sale
    $12.5M 48,480 shares at $258.15 15% of stake
    Traded Aug 5 Filed Aug 7
    ↗
  5. Elizabeth Forminard EVP, Chief Legal Officer
    Sale
    $4.1M 15,918 shares at $257.00 48% of stake
    Traded Aug 6 Filed Aug 7
    ↗
  6. Vanessa Broadhurst EVP, Global Corp Affairs
    Sale
    $5.8M 23,054 shares at $251.27 50% of stake
    Traded Jul 20 Filed Jul 21
    ↗
  7. Kathryn E Wengel EVP, Chief TO and Risk Officer
    Sale
    $2.4M 10,000 shares at $241.15 8% of stake
    Traded Jun 11 Filed Jun 12
    ↗
  8. Joaquin Duato CEO
    Sale
    $22.1M 100,000 shares at $221.23 76% of stake
    Traded Jan 26 Filed Jan 28
    ↗
  9. John G Morikis Director
    Buy
    $258K 1,250 shares at $206.15 +209% to stake
    Traded Nov 26, 2025 Filed Dec 1, 2025
    ↗
  10. John C Reed EVP, Innovative Medicine, R&D
    Sale
    $4.2M 21,721 shares at $192.71 67% of stake
    Traded Oct 17, 2025 Filed Oct 20, 2025
    ↗

Also filed in the last 12 months, not counted as buying or selling: 9 option exercises and 1 share withholding for taxes.

Congress

30 members of Congress traded JNJ in the last three years: 49 buys and 46 sales. 37 members listed it in 2025 annual reports.

All Congress trades
  1. Lloyd Doggett D-TX-37 Buy $1K–$15K Sep 8 filed Oct 5
  2. Thomas H. Kean, Jr. R-NJ-7 Partial sale $1K–$15K Aug 27 filed Sep 12
  3. John Boozman R-ARJoint Partial sale $1K–$15K Aug 20 filed Sep 11
  4. Richard McCormick R-GA-7 Sell $1K–$15K Jul 30 filed Aug 14
  5. Alan Armstrong R-OK Buy $1K–$15K Mar 30 filed Jul 21
  6. Alan Armstrong R-OK Buy $15K–$50K Mar 27 filed Jul 21

SEC filings

Recent issuer filings from EDGAR, 13 shown.

Filed Form Detail Links
10-Q Filing Doc
8-K 2.02,9.01 Filing Doc
8-K 5.02,9.01 Filing Doc
8-K 7.01,9.01 Filing Doc
8-K 7.01,9.01 Filing Doc
10-Q Filing Doc
8-K 2.02,9.01 Filing Doc
SCHEDULE 13G — Filing Doc
8-K 5.07,9.01 Filing Doc
10-Q Filing Doc
8-K 2.02,8.01,9.01 Filing Doc
SCHEDULE 13G/A — Filing Doc
SCHEDULE 13G/A — Filing Doc

Source: SEC EDGAR submissions, updated 9 days ago. All on EDGAR

Financials

US-GAAP annual figures by fiscal year, as tagged in Form 10-K. Each value links to its SEC filing.

Income statement

Metric FY2023 FY2024 FY2025
Revenue $79.99B $88.82B $94.19B
Gross profit $55.39B $61.35B $63.94B
Gross margin * 69.3% 69.1% 67.9%
Net income $17.94B $14.07B $26.8B
Net margin * 22.4% 15.8% 28.5%

Balance sheet

Metric FY2023 FY2024 FY2025
Total current assets $55.29B $55.89B $55.62B
Total non-current assets * $132.08B $124.21B $143.59B
Total assets $187.38B $180.1B $199.21B
Total current liabilities $55.8B $50.32B $54.13B
Total non-current liabilities * $54.77B $58.29B $63.54B

Cash flow

Metric FY2023 FY2024 FY2025
Cash from operations $21.19B $24.27B $24.53B
Cash from investing -$12.37B -$18.6B -$23.59B
Cash from financing -$8.87B -$3.13B -$5.54B
Net change in cash -$0.36B $2.25B -$4.4B

Source: SEC companyfacts (US-GAAP 10-K). A * marks a computed figure, not a single XBRL tag. Fiscal years are as the issuer labels them. Follow The Filings does not adjust or audit these figures.

Ownership over time

13Fs that reported it each quarter. Click a bar for that quarter’s holders.